Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia

M. Michieli, D. Damiani, A. Geromin, A. Michelutti, R. Fanin, D. Raspadori, D. Russo, G. Visani, A. Dinota, S. Pileri, T. Tsuruo, M. Grandi, M. Baccarani, S. Tura

Research output: Contribution to journalArticle

Abstract

Resistance to several cytotoxic agents, including anthracyclines, vinca alkaloids and epipodophylline derivatives (multidrug resistance, or MDR) can develop in tumor cells by overexpression of a 170-kd glycoprotein (p 170) which is an essential component of a membrane transport system leading to increased drug efflux and decreased intracellular drug concentration. By means of a p170-directed monoclonal antibody (MRK-16) and immunocytochemistry (alkaline phosphatase anti-alkaline phosphatase technique), we investigated the expression of p170 in marrow blast cells of 59 cases (38 at diagnosis and 21 in relapse) of acute-non-lymphocytic leukemia (ANLL). The proportion of strongly MDR-positive cells was higher in relapse than at diagnosis (median 15.5% vs 1.5%). Out of 31 patients who were evaluable for the results of first remission induction, failure of first-line treatment (including Daunorubicin, standard-dose and high-dose Arabinosyl Cytosine, and sometimes also Mitoxantrone) occurred in 8/22 MDR-positive cases and in 1/9 MDR-negative ones (p = 0.21). Failure of first-line treatment was always associated with a progressive increase of p 170 expression. Total failures (no remission plus early relapse) were more frequent (p = 0.001) among MDR-positive cases (16/22) than among the others (2/9). These data show that MDR is very frequent in ANLL also at diagnosis and suggest that MDR can contribute to early failure of standard treatment.

Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalEuropean Journal of Haematology
Volume48
Issue number2
Publication statusPublished - 1992

Fingerprint

Multiple Drug Resistance
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Glycoproteins
Recurrence
Alkaline Phosphatase
Vinca Alkaloids
Remission Induction
Mitoxantrone
Daunorubicin
Anthracyclines
Cytosine
Cytotoxins
Treatment Failure
Pharmaceutical Preparations
Bone Marrow
Immunohistochemistry
Monoclonal Antibodies
Membranes
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Michieli, M., Damiani, D., Geromin, A., Michelutti, A., Fanin, R., Raspadori, D., ... Tura, S. (1992). Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. European Journal of Haematology, 48(2), 87-92.

Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. / Michieli, M.; Damiani, D.; Geromin, A.; Michelutti, A.; Fanin, R.; Raspadori, D.; Russo, D.; Visani, G.; Dinota, A.; Pileri, S.; Tsuruo, T.; Grandi, M.; Baccarani, M.; Tura, S.

In: European Journal of Haematology, Vol. 48, No. 2, 1992, p. 87-92.

Research output: Contribution to journalArticle

Michieli, M, Damiani, D, Geromin, A, Michelutti, A, Fanin, R, Raspadori, D, Russo, D, Visani, G, Dinota, A, Pileri, S, Tsuruo, T, Grandi, M, Baccarani, M & Tura, S 1992, 'Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia', European Journal of Haematology, vol. 48, no. 2, pp. 87-92.
Michieli, M. ; Damiani, D. ; Geromin, A. ; Michelutti, A. ; Fanin, R. ; Raspadori, D. ; Russo, D. ; Visani, G. ; Dinota, A. ; Pileri, S. ; Tsuruo, T. ; Grandi, M. ; Baccarani, M. ; Tura, S. / Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. In: European Journal of Haematology. 1992 ; Vol. 48, No. 2. pp. 87-92.
@article{61a06155c3994b8080df821f0a0acf81,
title = "Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia",
abstract = "Resistance to several cytotoxic agents, including anthracyclines, vinca alkaloids and epipodophylline derivatives (multidrug resistance, or MDR) can develop in tumor cells by overexpression of a 170-kd glycoprotein (p 170) which is an essential component of a membrane transport system leading to increased drug efflux and decreased intracellular drug concentration. By means of a p170-directed monoclonal antibody (MRK-16) and immunocytochemistry (alkaline phosphatase anti-alkaline phosphatase technique), we investigated the expression of p170 in marrow blast cells of 59 cases (38 at diagnosis and 21 in relapse) of acute-non-lymphocytic leukemia (ANLL). The proportion of strongly MDR-positive cells was higher in relapse than at diagnosis (median 15.5{\%} vs 1.5{\%}). Out of 31 patients who were evaluable for the results of first remission induction, failure of first-line treatment (including Daunorubicin, standard-dose and high-dose Arabinosyl Cytosine, and sometimes also Mitoxantrone) occurred in 8/22 MDR-positive cases and in 1/9 MDR-negative ones (p = 0.21). Failure of first-line treatment was always associated with a progressive increase of p 170 expression. Total failures (no remission plus early relapse) were more frequent (p = 0.001) among MDR-positive cases (16/22) than among the others (2/9). These data show that MDR is very frequent in ANLL also at diagnosis and suggest that MDR can contribute to early failure of standard treatment.",
author = "M. Michieli and D. Damiani and A. Geromin and A. Michelutti and R. Fanin and D. Raspadori and D. Russo and G. Visani and A. Dinota and S. Pileri and T. Tsuruo and M. Grandi and M. Baccarani and S. Tura",
year = "1992",
language = "English",
volume = "48",
pages = "87--92",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia

AU - Michieli, M.

AU - Damiani, D.

AU - Geromin, A.

AU - Michelutti, A.

AU - Fanin, R.

AU - Raspadori, D.

AU - Russo, D.

AU - Visani, G.

AU - Dinota, A.

AU - Pileri, S.

AU - Tsuruo, T.

AU - Grandi, M.

AU - Baccarani, M.

AU - Tura, S.

PY - 1992

Y1 - 1992

N2 - Resistance to several cytotoxic agents, including anthracyclines, vinca alkaloids and epipodophylline derivatives (multidrug resistance, or MDR) can develop in tumor cells by overexpression of a 170-kd glycoprotein (p 170) which is an essential component of a membrane transport system leading to increased drug efflux and decreased intracellular drug concentration. By means of a p170-directed monoclonal antibody (MRK-16) and immunocytochemistry (alkaline phosphatase anti-alkaline phosphatase technique), we investigated the expression of p170 in marrow blast cells of 59 cases (38 at diagnosis and 21 in relapse) of acute-non-lymphocytic leukemia (ANLL). The proportion of strongly MDR-positive cells was higher in relapse than at diagnosis (median 15.5% vs 1.5%). Out of 31 patients who were evaluable for the results of first remission induction, failure of first-line treatment (including Daunorubicin, standard-dose and high-dose Arabinosyl Cytosine, and sometimes also Mitoxantrone) occurred in 8/22 MDR-positive cases and in 1/9 MDR-negative ones (p = 0.21). Failure of first-line treatment was always associated with a progressive increase of p 170 expression. Total failures (no remission plus early relapse) were more frequent (p = 0.001) among MDR-positive cases (16/22) than among the others (2/9). These data show that MDR is very frequent in ANLL also at diagnosis and suggest that MDR can contribute to early failure of standard treatment.

AB - Resistance to several cytotoxic agents, including anthracyclines, vinca alkaloids and epipodophylline derivatives (multidrug resistance, or MDR) can develop in tumor cells by overexpression of a 170-kd glycoprotein (p 170) which is an essential component of a membrane transport system leading to increased drug efflux and decreased intracellular drug concentration. By means of a p170-directed monoclonal antibody (MRK-16) and immunocytochemistry (alkaline phosphatase anti-alkaline phosphatase technique), we investigated the expression of p170 in marrow blast cells of 59 cases (38 at diagnosis and 21 in relapse) of acute-non-lymphocytic leukemia (ANLL). The proportion of strongly MDR-positive cells was higher in relapse than at diagnosis (median 15.5% vs 1.5%). Out of 31 patients who were evaluable for the results of first remission induction, failure of first-line treatment (including Daunorubicin, standard-dose and high-dose Arabinosyl Cytosine, and sometimes also Mitoxantrone) occurred in 8/22 MDR-positive cases and in 1/9 MDR-negative ones (p = 0.21). Failure of first-line treatment was always associated with a progressive increase of p 170 expression. Total failures (no remission plus early relapse) were more frequent (p = 0.001) among MDR-positive cases (16/22) than among the others (2/9). These data show that MDR is very frequent in ANLL also at diagnosis and suggest that MDR can contribute to early failure of standard treatment.

UR - http://www.scopus.com/inward/record.url?scp=0026591770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026591770&partnerID=8YFLogxK

M3 - Article

C2 - 1347749

AN - SCOPUS:0026591770

VL - 48

SP - 87

EP - 92

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -